Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease needing coronarography.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519012-14-00

Acronym

38RC19.186

Enrollment

66

Registered

2024-11-15

Start date

2020-09-15

Completion date

Unknown

Last updated

2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerotic cardiovascular disease

Brief summary

Index of microcirculatory resistance (IMR), measured during invasive coronary angiography (ICA) (in mmHg.s).

Detailed description

Troponin I level after PCI., Coronary angiography parameters and coronary physiology: % epicardial stenosis, FFR, CFR, IMR, Resting ultrasound parameters: systolic and diastolic function, myocardial deformation.

Interventions

DRUGRepatha 140 mg solution for injection in pre-filled pen

Sponsors

Centre Hospitalier Universitaire Grenoble Alpes

Lead SponsorOTHER

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Index of microcirculatory resistance (IMR), measured during invasive coronary angiography (ICA) (in mmHg.s).	—

Secondary

Measure	Time frame
Troponin I level after PCI., Coronary angiography parameters and coronary physiology: % epicardial stenosis, FFR, CFR, IMR, Resting ultrasound parameters: systolic and diastolic function, myocardial deformation.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026